Category: Statement

  • NIH Statement on World Asthma Day 2023

    NIH Statement on World Asthma Day 2023

    Today, the National Institutes of Health recognizes World Asthma Day and the innovative research that is helping to shed light on the disease, pave the way for effective treatments, and improve the lives of people who have asthma.

    In the United States alone, more than 25 million individuals — including more than 4 million children — experience asthma, which is a chronic lung disease that can cause coughing, wheezing, chest tightness, and shortness of breath. In severe cases, breathing becomes extremely difficult, and it feels like a weight compresses the chest. Worsening asthma can lead to missed time at school and work, emergency room visits, and even death.

    Several NIH institutes conduct and support asthma-related research, including the National Institute of Environmental Health Sciences (NIEHS); the National Heart, Lung, and Blood Institute (NHLBI); and the National Institute of Allergy and Infectious Diseases (NIAID). Each year, they come together to reaffirm the NIH commitment to studying asthma and enhancing patient care in the United States and globally.

    During the past year, NIH scientists and grant recipients advanced groundbreaking research that opens doors for new treatments and interventions, addresses disparities in asthma-related health outcomes, and expands our understanding of this chronic respiratory disease.

    Understanding Who Is at Risk, and Why

    NIEHS researchers discovered that frequent wood burning at home is linked to decreased lung function in adults with asthma. Many people in rural parts of the United States (and many individuals in other countries) burn wood and other biomass indoors for cooking and heating. People with asthma should consider reducing indoor wood burning or using air filtration devices, according to the scientists.

    Other NIEHS researchers found that following the 2010 Deepwater Horizon disaster, oil spill cleanup workers — many of whom were exposed to airborne contaminants, such as petroleum hydrocarbons — experienced increased risk of asthma. In the largest-ever study of its kind, the scientists analyzed data from nearly 25,000 cleanup workers and 8,000 nonworkers. The researchers showed that cleanup workers had a greater chance of developing asthma in the three years following the oil spill compared with nonworkers.

    NIAID-funded scientists found that increased levels of two outdoor air pollutants — ozone and fine particulate matter — are associated with non-viral asthma attacks in children and adolescents who live in low-income urban areas. The study also identified associations between exposure to the two pollutants and molecular changes in the children’s airways during non-viral asthma attacks, suggesting potential biological mechanisms involved in such attacks.

    Other NIAID-supported researchers discovered that the absence of a respiratory syncytial virus (RSV) infection in children before their first birthday is associated with a 26% lower risk of developing childhood asthma. RSV is the most common cause of severe lung disease in children younger than age one year in the United States. The finding represents additional evidence for a link between RSV infection in infancy and higher incidence of asthma at age five years. This evidence supports a need to study long-term respiratory outcomes among children in clinical trials of RSV prevention products such as vaccines.

    Research Lays Foundation for Improved Treatments

    Through the NHLBI-funded Severe Asthma Research Program, scientists are beginning to understand how asthma and obesity — conditions that often occur in the same people — might be related. Obesity can cause resistance to insulin, which is a hormone that controls blood sugar levels, and such resistance has been linked to asthma risk in adults.

    In a related NHLBI-funded study in people with severe asthma, scientists found that those with moderate or severe insulin resistance had lower lung function and did not respond as well to asthma treatment (steroids or bronchodilators). More clinical trials are needed to test whether treatments for insulin resistance can help prevent accelerated loss of lung function due to asthma, according to the researchers.

    Elsewhere, NIEHS grant recipients conducted a study in mice involving agricultural dust exposures, and they uncovered a novel role for the protein IL-22 in lung repair. Their findings could aid development of therapeutics for farmworkers and others experiencing environmentally induced lung diseases, such as asthma.

    Reducing Asthma Attacks in Disadvantaged Youth

    NIAID-supported researchers found that the monoclonal antibody mepolizumab decreased asthma attacks by 27% in Black and Hispanic children and adolescents who had a form of severe asthma, were prone to asthma attacks, and lived in low-income urban neighborhoods. This population has been underrepresented in previous clinical trials of asthma therapeutics.

    An analysis of gene activity in cells collected from study participants’ nasal secretions showed that mepolizumab tamped down the activity of three gene networks associated with allergic airway inflammation and asthma attacks but did not reduce the activity of six other networks related to tissue inflammation and mucus overproduction. These findings pave the way for using gene activation patterns to monitor new asthma therapies in future clinical trials involving this study population.

    Also, NIAID launched a clinical trial to test whether a different monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function in children with poorly controlled allergic asthma who live in low-income urban neighborhoods. Dupilumab is approved by the U.S. Food and Drug Administration as an add-on maintenance treatment for certain types of moderate-to-severe asthma in people aged 6 years and older. However, little data exist on the effectiveness of the drug in Black and Hispanic children, even though severe asthma disproportionately affects U.S. children in those groups. The NIAID study will help fill this knowledge gap.

    Addressing Disparities Through Collaboration

    In 2017, NHLBI launched a research program to improve asthma care for children on the Navajo Nation, which is the largest and most populous tribal reservation in the United States. Children on Navajo Nation are disproportionately affected by asthma. Due to the COVID-19 pandemic, scientists have only recently been able to return to the reservation, but the partnerships and training provided to tribal communities helped to maintain the program during the past few years. The initiative helps to increase access to asthma medication and education in schools, and to expand health-care provider training in asthma care. Details of the program are described in a 2022 journal article.

    Also, a school-based program that has demonstrated success in addressing asthma among disadvantaged youth in the Denver metropolitan area will be expanded to include five other regions of Colorado, including midsize cities and rural areas. Investigators leading these efforts are part of an NHLBI-supported alliance called DECIPHeR (Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk), which aims to engage with community stakeholders, understand their needs, and improve health outcomes.

    Zero-emissions Vehicles Reduce Emergency Room Visits

    NIEHS-funded scientists and their colleagues analyzed data on adoption of zero-emissions vehicles (ZEVs) in California and discovered an accompanying reduction in air pollution levels and asthma-related emergency room visits. ZEVs include battery electric, plug-in hybrid, and hydrogen fuel cell cars. The researchers identified a 3.2% drop in asthma-related emergency visits and a small reduction in nitrogen dioxide for every additional 20 ZEVs per 1,000 people.

    ZEVs may help to mitigate climate change and reduce health disparities in low-income neighborhoods, according to the researchers.

    Other NIEHS-funded researchers analyzed New York City’s Clean Fuel Bus Program from 2009 to 2014 and found that it led to significant reductions in concentrations of air pollutants that can contribute to asthma.


    About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

    About the National Institute of Allergy and Infectious Diseases (NIAID): NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

  • NIH Statement on World Asthma Day 2021

    NIH Statement on World Asthma Day 2021

    On World Asthma Day, the National Institutes of Health reaffirms its commitment to research to improve the lives of people with asthma. More than 25 million people in the United States have asthma, including 5.1 million children, according to the Centers for Disease Control and Prevention. This chronic lung disease can reduce quality of life, contributes to considerable emotional and financial stress, and is a major contributing factor to missed time from school and work. Severe asthma attacks can be life-threatening and may require emergency room visits and hospitalizations. Although asthma can affect anyone, some groups bear a disproportionate burden. For example, Black and Puerto Rican people are at higher risk of asthma than people of other races or ethnicities.

    The National Institute of Allergy and Infectious Diseases (NIAID); the National Heart, Lung, and Blood Institute (NHLBI); and the National Institute of Environmental Health Sciences (NIEHS) are the lead NIH institutes that support and conduct asthma research. Among many other advances, these institutes recently released updated evidence-based guidelines for the diagnosis, management and treatment of asthma; helped better define the relationship between asthma and COVID-19; and improved understanding of the numerous factors that can influence asthma severity.

    In December 2020, the NHLBI, with input from the National Asthma Education Prevention Program Coordinating Committee, announced the publication of updates to asthma management and treatment guidelines. The recommendations detailed in the 2020 Focused Updates to the Asthma Management Guidelines are designed to improve patient care and to support informed decision-making about clinical asthma management in six priority areas. These areas include use of inhaled corticosteroids, long-acting muscarinic antagonists, methods to reduce exposure to indoor allergen triggers, immunotherapy, fractional exhaled nitric oxide testing and bronchial thermoplasty.

    As a respiratory disease, COVID-19 has created particular concern and uncertainty for people with asthma. While some evidence suggests that moderate-to-severe asthma might increase risk for severe illness from COVID-19, two independent, NIAID-supported studies suggest that people with allergic asthma are not at higher risk and identify a potential mechanism. These studies found that people with asthma and allergic diseases have reduced expression of the human gene encoding the receptor on airway cells that SARS-CoV-2, the virus that causes COVID-19, uses to enter and infect cells. Results anticipated from the NIAID-led Human Epidemiology and Response to SARS-CoV-2 (HEROS) study will clarify whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not.

    In addition to respiratory infections, numerous environmental factors can influence asthma symptoms and severity. A NIEHS-funded study published last year was the first to link reduced emissions from coal-powered plants with asthma-related health benefits, including dramatic drops in asthma symptoms and hospitalizations. Another NIEHS-supported study found that children, especially boys, with elevated urine levels of bisphenol A (BPA)—a chemical used in food packaging and other consumer goods—had more asthma symptoms. Additional research suggests that exposure to bisphenol F and bisphenol S, two chemicals increasingly used as BPA substitutes, is associated with asthma and hay fever.

    The interplay between genetics and the environment also affects asthma susceptibility and severity. Two NIEHS studies helped clarify how an immune system protein called TLR5 may be involved in worsening asthma in response to environmental exposures. One study found that the lungs of people with a defective TLR5 generated much less inflammation after exposure to ozone than the lungs of healthy people. A companion study of people with asthma determined that participants who lacked a working TLR5 had fewer asthma symptoms upon exposure to house dust. NIAID-funded research provided additional insights into why some people develop asthma symptoms when exposed to household dust mites while others do not. In this study, scientists used cutting-edge genomics techniques to identify molecular features of T-cell subsets in people with asthma and allergy to dust mites.

    The complexity of asthma and the broad range of factors that influence an individual’s experience of the disease can pose challenges for managing the condition, suggesting the need for more personalized treatments. The NHLBI continues to support the Severe Asthma Research Program (SARP), a comprehensive study of adults and children with severe asthma, a debilitating form of the disease that often does not respond well to currently available medications. Findings from SARP informed the development of the NHLBI’s Precision Interventions for Severe and/or Exacerbation-Prone Asthma (PrecISE) Network Study. PrecISE will evaluate several novel and approved treatments for asthma by targeting them to defined groups of adults and teenagers with severe, poorly controlled asthma who share similar characteristics, such as genetic factors or biomarkers. A recent NIAID-funded study identified immune system characteristics that distinguish subgroups of patients with severe asthma resistant to standard treatment, further helping to pave the way for individually tailored treatments.

    NIH also remains dedicated to reducing the disproportionate burden of asthma among children living in low-income urban communities and certain minority populations. To extend the research performed previously by the NIAID-funded Inner City Asthma Consortium over several decades, NIAID recently funded a new clinical network initiative called Childhood Asthma in Urban Settings, or CAUSE. This program will investigate disease mechanisms and novel prevention and treatment strategies to mitigate the impact of asthma in disadvantaged child and adolescent populations. A recent NIH-funded study found new genetic variants linked to asthma severity in Puerto Rican children, who have high rates of asthma, that could lead to more targeted treatments in this group. The study includes genetic data from the NHLBI’s TOPMed Program, which seeks to understand the genetic underpinnings of disease, including asthma.

    As we reflect on the progress that has been made against asthma and the challenges that remain, NIH extends its gratitude to all who help make advances in care possible—from scientists and health care professionals to clinical research volunteers, advocates and educators. Together, we continue to advance our shared mission to develop and implement effective strategies for the management, treatment and prevention of this chronic lung disease.



    About the National Institute of Allergy and Infectious Diseases (NIAID): NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

    About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

    See all News Releases